Li Fang-Yang, Wang Yi-Hao, Zhang Cheng, Dang Wan-Yun, Wu Ze-Kun, Wu Zhen-Hui, Cui Jia-Lu, Wu Xiang-Jun, Yang Chun-Qi, Tian Xue-Cong, Xiao Cheng-Rong, Wang Yu-Guang, Gao Yue
School of Pharmacy, Guangdong Pharmaceutical University, Guang Zhou, 510006, China.
Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Chin Med. 2025 Jun 13;20(1):86. doi: 10.1186/s13020-025-01128-8.
The heart, as the body's blood-pumping organ, is extremely sensitive to changes in oxygen levels. Myocardial injury caused by hypoxia is a challenging issue, and there are currently no definitive specific drugs available for its treatment. Ginsenoside Rg5, one of the main rare saponins in ginseng, has shown significant efficacy in treating myocardial injury. This study aims to investigate the role and mechanisms of Rg5 in the treatment of hypoxic myocardial injury.
The cardioprotective effect against acute hypoxia of Rg5 was studied by assessing heart function, myocardial injury markers, inflammation, and oxidative stress in C57 mice, as well as apoptosis and reactive oxygen species (ROS) levels in H9c2 cardiomyocytes. Thermal proteome and target validation techniques were used to confirm the target protein of Rg5. The further protective mechanisms against hypoxia-induced damage were explored using immunocoprecipitation, immunofluorescence and rescue experiments in vivo and in vitro.
The experimental results demonstrated that Rg5 effectively improved cardiac function in mice, reduced inflammation, oxidative stress, and the release of myocardial injury markers, decreased cardiomyocyte apoptosis, and lowered ROS levels. Further, using target protein screening and validation techniques, Signal transducer and activator of transcription 3 (STAT3) was verified as a direct target for Rg5's cardioprotective effect. It was observed that Rg5 specifically promoted the phosphorylation of Tyr705 in STAT3 via the JAK2/STAT3 pathway, leading to the translocation of phosphorylated STAT3 into the nucleus where they induce the expression of anti-apoptotic protein and protect cells from hypoxic damage.
Rg5 could be a potential therapeutic agent for preventing and treating myocardial hypoxic injury, providing scientific evidence for its application in anti-hypoxic therapy.
心脏作为人体的血液泵器官,对氧水平变化极为敏感。缺氧引起的心肌损伤是一个具有挑战性的问题,目前尚无明确的特效药物用于治疗。人参皂苷Rg5是人参中主要的稀有皂苷之一,在治疗心肌损伤方面已显示出显著疗效。本研究旨在探讨Rg5在治疗缺氧性心肌损伤中的作用及机制。
通过评估C57小鼠的心功能、心肌损伤标志物、炎症和氧化应激,以及H9c2心肌细胞中的细胞凋亡和活性氧(ROS)水平,研究Rg5对急性缺氧的心脏保护作用。采用热蛋白质组学和靶点验证技术来确认Rg5的靶蛋白。利用体内和体外的免疫沉淀、免疫荧光和挽救实验,进一步探索其对缺氧诱导损伤的保护机制。
实验结果表明,Rg5有效改善了小鼠的心功能,减轻了炎症、氧化应激以及心肌损伤标志物的释放,减少了心肌细胞凋亡,并降低了ROS水平。此外,通过靶点蛋白筛选和验证技术,信号转导和转录激活因子3(STAT3)被确认为Rg5心脏保护作用的直接靶点。观察到Rg5通过JAK2/STAT3途径特异性促进STAT3中Tyr705的磷酸化,导致磷酸化的STAT3易位至细胞核,在细胞核中诱导抗凋亡蛋白的表达并保护细胞免受缺氧损伤。
Rg5可能是预防和治疗心肌缺氧损伤的潜在治疗药物,为其在抗缺氧治疗中的应用提供了科学依据。